35 terminated. 35 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Terminated 35 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 2 | Terminated 2 |
Follow Atopic Dermatitis: new trials by email Literature Review of Atopic Dermatitis trials Research Report on Atopic Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis Dupilumab, Placebo, IBI356 - Atopic Dermatitis | Phase 2 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 18 | 2025-12-31 | 2026-10-27 |
| Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis SAR444656 (KT-474), Placebo - Atopic Dermatitis | Phase 2 | Terminated | Sanofi | 70 | 2023-11-09 | 2026-11-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis LY3454738, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Eli Lilly and Company | 234 | 2023-06-21 | 2025-12-02 |
| A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified | Phase 2 / Phase 3 | Terminated | Pfizer | 58 | 2023-01-18 | 2025-05-08 |
| A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis BMX-010, Placebo - Atopic Dermatitis | Phase 2 | Terminated | BioMimetix JV, LLC | 103 | 2023-01-08 | 2024-04-18 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis AK002, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Allakos Inc. | 131 | 2022-06-27 | 2024-10-15 |
| Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation Application of Tralokinumab - Atopic Dermatitis | Phase 2 / Phase 3 | Terminated | University of Zurich | 24 | 2022-06-15 | 2026-02-06 |
| An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis RPT193, Placebo - Atopic Dermatitis | Phase 2 | Terminated | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 229 | 2022-06-07 | 2026-03-23 |
| A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials EDP1815 - Atopic Dermatitis | Phase 2 | Terminated | Evelo Biosciences, Inc. | 287 | 2022-06-06 | 2023-09-07 |
| Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD Broncho-Vaxom, Placebo - Atopic Dermatitis | Phase 2 | Terminated | OM Pharma SA | 63 | 2021-12-20 | 2023-08-08 |
| Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel DBI-001, Aqueous gel - Atopic Dermatitis | Phase 2 | Terminated | DermBiont, Inc. | 10 | 2021-10-06 | 2023-11-08 |
| Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Placebo, AK120 - Atopic Dermatitis | Phase 2 | Terminated | Akesobio Australia Pty Ltd | 79 | 2021-09-30 | 2025-02-26 |
| Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study FB-401 - Atopic Dermatitis | Phase 2 | Terminated | Forte Biosciences, Inc. | 36 | 2021-06-02 | 2021-10-28 |
| Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Benralizumab, Placebo / Benralizumab - Atopic Dermatitis | Phase 2 | Terminated | AstraZeneca | 194 | 2020-11-12 | 2023-08-31 |
| Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis DS107, Placebo - Atopic Dermatitis | Phase 2 | Terminated | DS Biopharma | 219 | 2019-09-19 | 2022-11-28 |
| Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Clobetasol propionate 0.05% Topical Oil - Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Hill Dermaceuticals, Inc. | 8 | 2019-09-09 | 2021-06-23 |
| Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo J. lividum - Atopic Dermatitis | Phase 2 | Terminated | DermBiont, Inc. | 9 | 2019-05-20 | 2021-06-18 |
| A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients ZPL389 30mg, ZPL389 50mg, TCS and/or TCI - Atopic Dermatitis | Phase 2 | Terminated | Novartis Pharmaceuticals | 123 | 2019-04-04 | 2021-10-08 |
| A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis MOR106, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 33 | 2019-03-25 | 2021-01-05 |
Showing 20 of 35. Sign in to see all of them.
Dermatitis, Atopic (35) · Eczema (10) · Dermatitis (6) · Pruritus (4) · Lymphoma, Follicular (3) · Skin Diseases (3) · Immune System Diseases (2) · Alopecia (1) · Inflammation (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Psoriasis (1) · Skin Diseases, Eczematous (1) · Staphylococcal Infections (1) · Striae Distensae (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35) · Genetic Diseases, Inborn (35) · Hypersensitivity (35) · Hypersensitivity, Immediate (35) · Skin Diseases, Genetic (35) · Skin and Connective Tissue Diseases (35) · Skin Diseases, Eczematous (34) · Immune System Diseases (33) · Skin Diseases (32) · Dermatitis (29) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (5) · Skin Manifestations (5) · Hemic and Lymphatic Diseases (4) · Immunoproliferative Disorders (4)
dupilumab (2) · itepekimab (2) · 8,11,14-Eicosatrienoic Acid (1) · AK002 (1) · BANG polymer gel (1) · Broncho-Vaxom (1) · Clobetasol (1) · Oils (1) · Therapeutics (1) · antroquinonol (1) · benralizumab (1) · etrasimod (1) · gusacitinib (1) · halobetasol (1) · tezepelumab (1)
Regeneron Pharmaceuticals (3) · DermBiont, Inc. (2) · Eli Lilly and Company (2) · Lakefront Biotherapeutics NV (2) · Novartis Pharmaceuticals (2) · Akesobio Australia Pty Ltd (1) · Allakos Inc. (1) · Amgen (1) · Asana BioSciences (1) · AstraZeneca (1) · BioMAS Ltd (1) · BioMimetix JV, LLC (1) · Celsus Therapeutics PLC (1) · Chung Shan Medical University (1) · DS Biopharma (1)
United States (25) · Poland (14) · Germany (13) · Canada (11) · Czechia (7) · Hungary (6) · Japan (6) · Spain (6) · Australia (5) · South Korea (5) · United Kingdom (5) · Taiwan (4) · Austria (3) · Belgium (3) · Finland (3)
Alex Zvulunov, Prof (1) · Avner Shemer, Prof (1) · Ben Ehst, PhD (1) · Chin Lee, MD, MPH (1) · Daisy Blanco, MD (1) · Dalia Gilat, Dr. (1) · David Zammit, Ph.D. (1) · Douglas Maslin, MD (1) · Eli Sprecher, Prof (1) · Emma Guttman, MD, PhD (1) · Felix Pavlotsky, MD (1) · Franziska Rueff, Professor (1)
2018 (5), 2017 (1), 2023 (1)